Lanreotide Acetate | CAS 108736-35-2 / 127984-74-1 | Somatostatin Analogue (Research Use Only) | Knowlux

Product Description

Lanreotide Acetate, CAS 127984-74-1 (acetate salt) / 108736-35-2 (free peptide), is a synthetic cyclic octapeptide somatostatin analogue supplied by Knowlux for laboratory research use. The sequence is D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, with a disulfide bridge between Cys2 and Cys7. The molecular formula is C54H69N11O10S2 and the molecular weight is 1096.32 g/mol (free peptide basis). Each lot is released with a lot-specific COA, MSDS and analytical traceability.

CAS and Salt Form Clarification: Two registries are commonly cited for this product. CAS 108736-35-2 corresponds to the free peptide (Lanreotide), while CAS 127984-74-1 corresponds to the acetate salt (Lanreotide Acetate), as confirmed by the Japanese Accepted Names database and Sigma-Aldrich. Many Chinese supplier listings on ChemicalBook use 108736-35-2 regardless of salt form, which creates ambiguity when comparing specifications or pricing. A third CAS, 2378114-72-6, appears in some peptide databases for a different acetate stoichiometry (C56H73N11O12S2, MW 1156.38) and should not be used interchangeably without supplier confirmation. Knowlux declares the salt basis and acetate content per lot on the COA. Buyers should confirm whether the quoted material is free peptide or acetate salt before procurement.

Sequence Verification Note: The correct sequence, confirmed by ChemicalBook and PeptideDB, is H-D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 with a disulfide bridge between Cys2 and Cys7. The N-terminal residue is D-2-naphthylalanine (D-2-Nal), a non-natural amino acid that contributes to receptor binding affinity and metabolic stability.

Product Parameters

Product Details

1. Overview

Lanreotide is a synthetic, long-acting somatostatin analogue with high binding affinity for somatostatin receptor subtype 2 (SSTR2). It is structurally related to octreotide but contains a D-2-naphthylalanine residue at the N-terminus, which confers enhanced receptor binding and prolonged metabolic stability. In clinical medicine, lanreotide acetate is approved for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors. However, the material supplied under this specification is research-grade and is not intended for human administration. Knowlux supplies this compound strictly for laboratory investigation of somatostatin receptor signaling and related pharmacological pathways.

2. Structural Profile

The octapeptide backbone comprises eight residues with a disulfide bridge cyclising Cys2 and Cys7. The D-2-Nal1 substitution replaces the natural phenylalanine found in somatostatin, increasing lipophilicity and receptor affinity. D-Trp4 further contributes to metabolic stability against peptidase degradation. The C-terminal threoninamide is amidated, protecting against carboxypeptidase attack. These modifications collectively yield a peptide with a substantially longer half-life than native somatostatin (approximately 90 minutes versus 1 to 3 minutes) in preclinical models.

3. Research Applications

Published pharmacological characterizations describe the following research applications:

• Somatostatin receptor (SSTR2, SSTR5) binding and functional assays

• Inhibition of growth hormone and hormone secretion in pituitary cell models

• Neuroendocrine tumor cell proliferation studies

• Polycystic kidney and liver disease research models

• Reference standard development for HPLC and LC-MS analytical methods

One published study demonstrated that lanreotide inhibited proliferation of dispersed human non-functioning pituitary adenoma cells in vitro, with involvement of tyrosine phosphatase activation and inhibition of voltage-sensitive calcium channels. These descriptions are derived from published research and are provided for scientific reference only. They do not constitute clinical guidance or dosing recommendations.

Quality Control

Solubility and Handling

Solubility: Lanreotide Acetate is soluble in water. Supplier data indicates aqueous solubility suitable for stock preparation. DMSO solubility is supplier-dependent and should be confirmed on the lot-specific technical sheet. Prepare solutions fresh and aliquot to avoid repeated freeze-thaw cycles.

Handling Precautions: Use powder-handling containment (glove box or fume hood with particulate control). Avoid inhalation of fine powder. Wear nitrile gloves, lab coat, and eye protection. Follow institutional chemical hygiene plans for research peptides. The disulfide bridge is sensitive to reducing agents; avoid contact with dithiothreitol (DTT) or mercaptoethanol during handling.

Storage and Stability

Documentation Support

Per lot: COA, MSDS, certificate of origin, HPLC chromatogram, and mass spectrometry data. Sequence verification data and counter-ion specification available on request. Custom specifications and third-party inspection can be arranged on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

FOR RESEARCH USE ONLY. NOT FOR HUMAN USE. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Lanreotide is an approved medicinal product in certain jurisdictions for specific clinical indications; however, the material offered under this specification is research-grade and is not intended for clinical use. The purchaser is responsible for verifying product specifications against their specific research requirements and for compliance with all applicable institutional, local, and national regulations governing research chemical acquisition, storage, and use. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.